MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-10-2022
Viveve Medical Accounts Receivables 2011-2026 | VIVE
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Viveve Medical
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 549 K | 770 K | 1.57 M | 5.7 M | 6.21 M | 2.09 M | 593 K | 6 K | 502 K | 402 K | 453 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.21 M | 6 K | 1.71 M |
Quarterly Accounts Receivables Viveve Medical
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 860 K | 801 K | 509 K | 549 K | 514 K | 696 K | 336 K | 770 K | 770 K | 770 K | 770 K | 1.57 M | 1.57 M | 1.57 M | 1.57 M | 5.7 M | 5.7 M | 5.7 M | 5.7 M | 6.21 M | 6.21 M | 6.21 M | 6.21 M | 2.09 M | 2.09 M | 2.09 M | 2.09 M | 593 K | 593 K | 593 K | 593 K | 6 K | 6 K | 6 K | 6 K | 502 K | 488 K | 210 K | 502 K | 402 K | 402 K | 402 K | 402 K | 453 K | 453 K | 453 K | 453 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.21 M | 6 K | 1.64 M |
Accounts Receivables of other stocks in the Medical devices industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BioSig Technologies
BSGM
|
109 K | - | 37.08 % | $ 85.7 M |  USA |
 |
Axonics Modulation Technologies
AXNX
|
44.8 M | - | - | $ 3.31 B | USA |
 |
Dynatronics Corporation
DYNT
|
2.8 M | - | 14.99 % | $ 929 K | USA |
 |
Aziyo Biologics
AZYO
|
1.73 M | - | 1.37 % | $ 20.5 M | USA |
 |
Align Technology
ALGN
|
996 M | $ 165.05 | -6.92 % | $ 12.4 B | USA |
 |
Acutus Medical
AFIB
|
11.4 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
2.37 M | - | 3.58 % | $ 2.21 M | USA |
 |
Alphatec Holdings
ATEC
|
97.3 M | $ 10.98 | -4.69 % | $ 1.65 B | USA |
 |
Conformis
CFMS
|
9.77 M | - | - | $ 16.4 M | USA |
 |
Abbott Laboratories
ABT
|
7.93 B | $ 105.06 | 0.47 % | $ 183 B | USA |
 |
Accuray Incorporated
ARAY
|
83.2 M | $ 0.39 | 3.73 % | $ 40.1 M | USA |
 |
Cardiovascular Systems
CSII
|
39.7 M | - | 0.15 % | $ 844 M | USA |
 |
Second Sight Medical Products
EYES
|
455 K | - | -0.97 % | $ 54.4 M | USA |
 |
Apollo Endosurgery
APEN
|
15 M | - | - | $ 475 M | USA |
 |
Bruker Corporation
BRKR
|
566 M | $ 34.24 | -3.13 % | $ 5.1 K | USA |
 |
ClearPoint Neuro
CLPT
|
6.55 M | $ 9.18 | -2.25 % | $ 260 M | USA |
 |
Avinger
AVGR
|
1.01 M | - | -20.74 % | $ 369 K | USA |
 |
Electromed
ELMD
|
24.7 M | $ 24.63 | 0.74 % | $ 208 M | USA |
 |
CONMED Corporation
CNMD
|
248 M | $ 35.38 | -3.44 % | $ 1.1 B | USA |
 |
Establishment Labs Holdings
ESTA
|
77.5 M | $ 55.71 | -7.01 % | $ 1.65 B |  Costa-rica |
 |
NanoVibronix
NAOV
|
98 K | - | - | $ 1.08 M | USA |
 |
Helius Medical Technologies
HSDT
|
117 K | $ 1.92 | -4.48 % | $ 1.17 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
272 M | $ 9.32 | -0.64 % | $ 718 M | USA |
 |
Inogen
INGN
|
38.9 M | $ 6.27 | -3.54 % | $ 167 M | USA |
 |
Cytosorbents Corporation
CTSO
|
7.32 M | $ 0.59 | -1.5 % | $ 32.1 M | USA |
 |
Aethlon Medical
AEMD
|
128 K | $ 2.24 | -1.32 % | $ 3.5 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
660 M | $ 78.78 | -4.04 % | $ 46.1 B | USA |
 |
BIOLASE
BIOL
|
5.48 M | - | -13.19 % | $ 166 K | USA |
 |
AdaptHealth Corp.
AHCO
|
371 M | $ 11.25 | -1.4 % | $ 1.52 B | USA |
 |
Penumbra
PEN
|
190 M | $ 335.11 | -0.39 % | $ 13 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
53.8 M | $ 15.72 | -3.85 % | $ 369 M | USA |
 |
LivaNova PLC
LIVN
|
216 M | $ 61.25 | -3.77 % | $ 3.34 B |  Britain |
 |
Invacare Corporation
IVC
|
88 M | - | - | $ 24.7 M | USA |
 |
Ra Medical Systems
RMED
|
21 K | - | 10.0 % | $ 610 K | USA |
 |
IRIDEX Corporation
IRIX
|
6.73 M | $ 0.99 | -26.48 % | $ 16 M | USA |
 |
IRadimed Corporation
IRMD
|
13.7 M | $ 97.44 | -1.32 % | $ 1.24 B | USA |
 |
Myomo
MYO
|
4.1 M | $ 0.67 | -1.56 % | $ 28 M | USA |